Picotamide in migraine aura prevention: a pilot study.

Area of Science:

• Neurology
• Pharmacology

Background:

• Migraine aura (MA) presents a significant challenge in neurological care.
• Current prophylactic treatments for MA have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy of picotamide, an antiplatelet agent, in the prophylactic treatment of migraine aura.
• To assess the impact of picotamide on MA frequency, duration, and associated symptomatology.

Main Methods:

• An open, preliminary trial involving 22 women with diagnosed migraine aura.
• A nine-month study including a three-month drug-free run-in period followed by six months of picotamide treatment (300 mg twice daily).
• Patients maintained detailed diaries to record MA frequency, duration, and neurological symptoms.

Main Results:

• A significant decrease in MA frequency was observed, from 6.85 in the run-in period to 2.85 during the first trimester and 2.55 during the second trimester of treatment.
• MA duration significantly reduced from 36.75 minutes to 20.00 minutes in the first trimester and 17.75 minutes in the second trimester.
• Twenty-five percent of patients experienced complete resolution of MA, and neurological symptoms associated with aura showed positive modification. No serious adverse events were reported.

Conclusions:

• Picotamide demonstrates significant efficacy in reducing the frequency and duration of migraine aura.
• The therapeutic benefits of picotamide are evident early in treatment and are sustained over the six-month study period.
• Picotamide represents a potentially effective and safe option for the prophylactic management of migraine aura.